A quantitative study on the impact of a community falls pharmacist role, on medicines optimisation in older people at risk of falls.
Deprescribing
Falls Risk increasing drugs (FRIDs)
Medicines optimisation
Older people
Polypharmacy
Journal
BMC geriatrics
ISSN: 1471-2318
Titre abrégé: BMC Geriatr
Pays: England
ID NLM: 100968548
Informations de publication
Date de publication:
15 Jul 2024
15 Jul 2024
Historique:
received:
22
01
2024
accepted:
01
07
2024
medline:
16
7
2024
pubmed:
16
7
2024
entrez:
15
7
2024
Statut:
epublish
Résumé
The World Falls guidance includes medication review as part of its recommended multifactorial risk assessment for those at high risk of falling. Use of Falls Risk Increasing Drugs (FRIDs) along with polypharmacy and anticholinergic burden (ACB) are known to increase the risk of falls in older people. The impact of a community falls pharmacist within a hospital Trust, working as part of a multi-professional community falls prevention service, was evaluated in 92 people aged 65 years or older, by analysing data before and after pharmacist review, namely: number and type of FRIDs prescribed; anticholinergic burden score using ACBcalc Following pharmacist review, there was a reduction in polypharmacy (mean number of medicines prescribed per patient reduced by 8%; p < 0.05) and anticholinergic burden score (average score per patient reduced by 33%; p < 0.05). Medicines appropriateness improved (Medicines Appropriateness Index score decreased by 56%; p < 0.05). There were 317 clinically significant interventions by the community falls pharmacist. One hundred and one FRIDs were deprescribed. Annual cost avoidance and drug cost savings were £40,689-£82,642 and avoidable carbon dioxide (CO The community falls pharmacist role increases prescribing appropriateness in the older population at risk of falls, and is an effective and cost-efficient means to optimise medicines in this population, as well as having a positive impact on the environment.
Sections du résumé
BACKGROUND
BACKGROUND
The World Falls guidance includes medication review as part of its recommended multifactorial risk assessment for those at high risk of falling. Use of Falls Risk Increasing Drugs (FRIDs) along with polypharmacy and anticholinergic burden (ACB) are known to increase the risk of falls in older people.
METHOD
METHODS
The impact of a community falls pharmacist within a hospital Trust, working as part of a multi-professional community falls prevention service, was evaluated in 92 people aged 65 years or older, by analysing data before and after pharmacist review, namely: number and type of FRIDs prescribed; anticholinergic burden score using ACBcalc
RESULTS
RESULTS
Following pharmacist review, there was a reduction in polypharmacy (mean number of medicines prescribed per patient reduced by 8%; p < 0.05) and anticholinergic burden score (average score per patient reduced by 33%; p < 0.05). Medicines appropriateness improved (Medicines Appropriateness Index score decreased by 56%; p < 0.05). There were 317 clinically significant interventions by the community falls pharmacist. One hundred and one FRIDs were deprescribed. Annual cost avoidance and drug cost savings were £40,689-£82,642 and avoidable carbon dioxide (CO
CONCLUSION
CONCLUSIONS
The community falls pharmacist role increases prescribing appropriateness in the older population at risk of falls, and is an effective and cost-efficient means to optimise medicines in this population, as well as having a positive impact on the environment.
Identifiants
pubmed: 39009970
doi: 10.1186/s12877-024-05189-6
pii: 10.1186/s12877-024-05189-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
604Informations de copyright
© 2024. The Author(s).
Références
Office for Health Improvement & Disparities (OHID). Falls and fractures: applying all Our Health. Updated Febr 2022 https://www.gov.uk (1 September 2023, last accessed).
Hill AM, Etherton-Beer C, McPhail SM, et al. Reducing falls after hospital discharge: a protocol for a randomised controlled trial evaluating an individualised multimodal falls education programme for older adults. BMJ Open. 2017;7:e013931.
doi: 10.1136/bmjopen-2016-013931
pubmed: 28153933
pmcid: 5293998
Montero-Odasso M, van der Velde N, Martin FC, et al. The Task Force on Global guidelines for Falls in older adults, World guidelines for falls prevention and management for older adults: a global initiative. Age Ageing. 2022;51:9.
doi: 10.1093/ageing/afac205
Saeed D, Miller R, Darcy C et al. Medication-related fall (MRF) screening and scoring tool: consensus Delphi validation. International Journal of Pharmacy Practice. 2022; (Supplement_1): i41-i42. https://doi.org/10.1093/ijpp/riac019.057 .
National Institute Health and Care Excellence (NICE). Falls in Older People: Assessing risk and prevention Guidance 2013. https://www.nice.org.uk (4 September 2023, last accessed).
Duerden M, Avery T, Payne R Polypharmacy and medicines optimisation, editors. Making it safe and sound. The Kings Fund 2013; In: Brown A, editor. The King’s Fund. https://www.kingsfund.org.uk/publications .
Smith H, Miller K, Barnett N et al. Person-centred care including deprescribing for older people. Pharm (Basel) 2019; 7.
Reeve E, Thompson W, Farrell B, Deprescribing. A narrative review of the evidence and practical recommendations for recognizing opportunities and taking action. Eur J Intern Med. 2017;38:3–11.
doi: 10.1016/j.ejim.2016.12.021
pubmed: 28063660
Rambhade S, Chakarborty A, Shrivastava A, Patil UK. Rambhade A. A survey on polypharmacy and use of inappropriate medications. Toxicol Int. 2012;19:68–73.
doi: 10.4103/0971-6580.94506
pubmed: 22736907
pmcid: 3339249
Dhalwani N, Fahami R, Sathanapally H, Seidu S, Davies MJ, Khunti K. Association between polypharmacy and falls in older adults: a longitudinal study from England. BMJ Open. 2017;7:e016358.
doi: 10.1136/bmjopen-2017-016358
pubmed: 29042378
pmcid: 5652576
McMichael AJ, Zafeiridi E, Ryan M. Anticholinergic drug use and risk of mortality for people with dementia in Northern Ireland. Aging Ment Health. 2021;25:1475–82.
doi: 10.1080/13607863.2020.1830028
pubmed: 33073601
Mehdizadeh D, Hale M, Todd O, et al. Associations between anticholinergic medication exposure and adverse health outcomes in older people with Frailty: a systematic review and Meta-analysis. Drugs Real World Outcomes. 2021;8:431–58.
doi: 10.1007/s40801-021-00256-5
pubmed: 34164795
pmcid: 8605959
Todd C, Skelton D. What are the main risk factors for falls among older people and what are the most effective interventions to prevent these falls? World Health Organisation Health Evidence Network report. 2004; https://www.euro.who.int .
Northern Ireland Medicines Optimisation Quality Framework. Department of Health,Social Services and Public Safety 2016.
Fracture Risk Assessment Tool (FRAX
Anticholinergic Burden Calculator web. app (ACBcalc
Lisibach A, Benelli V, Ceppi MG, et al. Quality of anticholinergic burden scales and their impact on clinical outcomes: a systematic review. Eur J Clin Pharmacol. 2021;77:147–62.
doi: 10.1007/s00228-020-02994-x
pubmed: 33011824
Hanlon JT, Schmader KE, Samsa GP, et al. A method for assessing drug therapy appropriateness. J Clin Epidemiol. 1992;45(10):1045–51.
doi: 10.1016/0895-4356(92)90144-C
pubmed: 1474400
Hanlon JT, Schmader KE. The medication appropriateness index: a clinimetric measure. Psychother Psychosom. 2022;91(2):78–83.
doi: 10.1159/000521699
pubmed: 35158365
Eadon H. Assessing the quality of ward pharmacists’ interventions. Int J Pharm Pract. 1992;1(3):145–7.
doi: 10.1111/j.2042-7174.1992.tb00556.x
Royal College of Physicians, London. Measurement of lying and standing blood pressure: A brief guide for clinical staff 2017 [Online]. Available: https://www.rcplondon.ac.uk [22 August 2022 last accessed].
Karnon J, Mcintosh A, Dean J et al. 2008. Modelling the expected net benefits of interventions to reduce the burden of medication errors. J Health Serv Res Policy 2008; 13: 85–91.
Mair A, Scott M, Kirke C. iSimpathy Evaluation Rep Edinb 2023 ISBN978-1-3999-6298-8.
Health & Personal Social Services Northern Ireland, Business Services Organisation September. 2023; Drug Tariff https://www.hscni.net (3 September 2023, last accessed).
Environmental impact report. Medicines Optimisation. Implementing the NICE guideline on medicines optimisation (NG5) 2015; Proof of concept v1.7 https://Medicines-optimisation-sustainability-report.pdf (nice.org.uk).
Royal Osteoporosis Society Healthy Living for Strong Bones Leaflet. Available at: https://www.ncbi.nlm.nih.gov (20 August 2023, last accessed).
UK National Osteoporosis Guideline Group (NOGG). The Prevention and Treatment of Osteoporosis 2022; Available at: https://www.sheffield.ac.uk/NOGG/manual_data_entry.html.
Browne C, Kingston C, Keane C. Falls prevention focused medication review by a pharmacist in an acute hospital: implications for future practice. Int J Clin Pharm. 2014;36:969–75.
doi: 10.1007/s11096-014-9980-3
pubmed: 25108410
Bennett A, Gnjidic D, Gillett M, et al. Prevalence and impact of fall-risk-increasing drugs, polypharmacy, and drug-drug interactions in robust versus frail hospitalised falls patients: a prospective cohort study. Drugs Aging. 2014;31:225–32.
doi: 10.1007/s40266-013-0151-3
pubmed: 24452921
Kalim RA, Cunningham CJ, Ryder SA, McMahon NM. Deprescribing medications that increase the risk of Falls in Older people: exploring doctors’ perspectives using the theoretical domains Framework (TDF). Drugs Aging. 2022;39:935–47.
doi: 10.1007/s40266-022-00985-4
pubmed: 36409404
pmcid: 9676799
Wallis K, Andrews A, Henderson M. Swimming against the tide: primary care physician’s views on deprescribing in everyday practice. Ann Fam Med 2017; 15(4).
Gillespie RJ, Harrison L, Mullan J. Deprescribing medications for older adults in the primary care context: a mixed studies review. Health Sci Rep 2018; 1e45.
Peat G, Fylan B, Marques I, et al. Barriers and facilitators of successful deprescribing as described by older patients living with frailty, their informal carers and clinicians: a qualitative interview study. BMJ Open. 2022;12:e054279. https://doi.org/10.1136/bmjopen-2021-054279 .
doi: 10.1136/bmjopen-2021-054279
pubmed: 35351709
pmcid: 8961139
Thompson W, Farrell B. Deprescribing: what is it and what does the evidence tell us? Can J Hosp Pharm. 2013;66:201–2.
pubmed: 23814291
pmcid: 3694945
Spinewine A, Swine C, Dhillon S, Lambert P, Nachega JB, Wilmotte L, Tulkens PM. Effect of a collaborative approach on the quality of prescribing for geriatric inpatients: a randomized, controlled trial. J Am Geriatr Soc. 2007;55(5):658 – 65. https://doi.org/10.1111/j.1532-5415.2007.01132.x . PMID: 17493184.
Kaufmann CP, Tremp R, Hersberger KE, Lampert ML. Inappropriate prescribing: a systematic overview of published assessment tools. Eur J Clin Pharmacol. 2014;70(1):1–11. https://doi.org/10.1007/s00228-013-1575-8 . Epub 2013 Sep 10. PMID: 24019054.
doi: 10.1007/s00228-013-1575-8
pubmed: 24019054
Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. Tools for Assessment of the Appropriateness of Prescribing and Association with Patient-Related Outcomes: A Systematic Review. Drugs Aging. 2018;35(1):43–60. https://doi.org/10.1007/s40266-018-0516-8 . PMID: 29350335.
Curtin D, Gallagher PF, O’Mahony D. Explicit criteria as clinical tools to minimize inappropriate medication use and its consequences. Ther Adv Drug Saf. 2019;10:2042098619829431. https://doi.org/10.1177/2042098619829431 . PMID: 30800270; PMCID: PMC6378636.
doi: 10.1177/2042098619829431
pubmed: 30800270
pmcid: 6378636
American Geriatrics Society Beers Criteria
doi: 10.1111/jgs.18372
O’Mahony D, Cherubini A, Guiteras AR, Denkinger M, Beuscart JB, Onder G, Gudmundsson A, Cruz-Jentoft AJ, Knol W, Bahat G, van der Velde N, Petrovic M, Curtin D. STOPP/START criteria for potentially inappropriate prescribing in older people: version 3. Eur Geriatr Med. 2023;14(4):625–632. doi: 10.1007/s41999-023-00777-y. Epub 2023 May 31. Erratum in: Eur Geriatr Med. 2023;14(4):633. https://doi.org/10.1007/s41999-023-00812-y . PMID: 37256475; PMCID: PMC10447584.
Lotta J, Seppala M, Petrovic J, Ryg G, Bahat E, Topinkova K, Szczerbińska, Tischa JM, van der Cammen S, Hartikainen B, Ilhan F, Landi Y, Morrissey A, Mair M, Gutiérrez-Valencia MH, Emmelot-Vonk. María Ángeles Caballero Mora, Michael Denkinger, Peter Crome, Stephen H D Jackson, Andrea Correa-Pérez, Wilma Knol, George Soulis, Adalsteinn Gudmundsson, Gijsbertus Ziere, Martin Wehling, Denis O’Mahony, Antonio Cherubini, Nathalie van der Velde, STOPPFall (Screening Tool of Older Persons Prescriptions in older adults with high fall risk): a Delphi study by the EuGMS Task and Finish Group on Fall-Risk-Increasing Drugs, Age and Ageing,2021; Volume 50, Issue 4, Pages 1189–1199, https://doi.org/10.1093/ageing/afaa249 .
Seppala LJ, Van Der Velde N, Masud T, et al. EuGMS Task and Finish group on fall-risk-increasing drugs (FRIDs): position on knowledge dissemination, management, and Future Research. Drugs Aging. 2019;36:299–307.
doi: 10.1007/s40266-018-0622-7
pubmed: 30741371
pmcid: 6435622
Miller R, Darcy CM, Friel A, Scott M, Toner S. Consultant pharmacist case management of older people in intermediate care. EJPCH. 2016;4(1):46–52.
doi: 10.5750/ejpch.v4i1.1056
Gompertz D. Show me your meds, please’: the impact of home-based medicines assessments. PJ. 2023;310:7973.
Holley-Moore G, Creighton H. The Future of Transport in an Ageing Society 2015;, Age UK. https://www.ilcuk.org.uk last accessed 12/10/2023).
Steel N, Ford AJ, Newton JN, et al. Changes in health in the countries of the UK and 150 English Local Authority areas 1990–2016: a systematic analysis for the global burden of Disease Study 2016. Volume 392. Lancet; 2018. pp. 1647–61.
Cleland B, Wallace J, Bond RR, et al. Insights into antidepressant prescribing using Open Health data. Big Data Res. 2018;12:41–8.
doi: 10.1016/j.bdr.2018.02.002
de Vries M, Seppala LJ, Daams JG et al. Fall-risk-increasing drugs: a systematic review and Meta Analysis: I. Cardiovascular drugs. J Am Med Dir Assoc 2018; 19(4): 371 e1- e9.
Seppala LJ, Wermelink A, de Vries M et al. Fall-Risk-IncreasingDrugs:ASystematicReviewandMeta-Analysis:II.Psychotropics. J. Am Med Dir Assoc. 2018; 19(4): 371 e11-e17. Accession Number: 29402652 https://doi.org/10.1016/j.jamda.2017.12.098 .
Seppala LJ, van de Glind EMM, Daams JG et al. Fall-Risk Increasing Drugs: A Systematic Review and Meta Analysis: III. Others. J Am Med Dir Assoc. 2018; 19(4): 372 e1-372 e8. Accession Number: 29402646 https://doi.org/10.1016/j.jamda.2017.12.099 . https://www.ncbi.nlm.nih.gov/pubmed/29402646 .
Gemmeke M, Koster ES, Van der Velde N, Taxis K, Bouvy ML. Establishing a community pharmacy-based fall prevention service – an implementation study. Res Social Adm Pharm. 2023;19:155–66.
doi: 10.1016/j.sapharm.2022.07.044
pubmed: 35995694
Mott DA, Martin B, Breslow R, Michaels B, Kircher J, Mahoney J, Margolis A. Impact of a medication therapy management intervention targeting medications associated with falling: results of a pilot study. J Am Pharm Assoc. 2016;56:22–8.
doi: 10.1016/j.japh.2015.11.001